Cases That Test Your Skills

From sweet to belligerent in the blink of an eye

Author and Disclosure Information

 

References

On hospital Day 13, Ms. P’s behavior declines again. She screams profanities at staff and does not recognize the clinicians who have been providing care to her. The physician initiates valproic acid, 125 mg, 3 times a day, to target Ms. P’s behavioral disturbances. A pharmacist notes that the patient’s sotalol could be contributing to Ms. P’s psychiatric presentation, and that based on her eCrCl level of 33 mL/min/1.73 m2, a dosage adjustment or medication change might be warranted.

On Day 14, Ms. P displays erratic behavior and intermittent tachycardia. A cardiac consultation is ordered. A repeat ECG reveals atrial fibrillation with rapid rate and a QT/QTc of 409/432 ms. Ms. P is transferred to the telemetry unit, where the cardiologist discontinues sotalol because the dosage is not properly renally adjusted. Sotalol hydrochloride has been associated with life-threatening ventricular tachycardia.8 Diltiazem, 30 mg every 6 hours is initiated to replace sotalol.

By Day 16, the treatment team notes improved cognition and behavior. On Day 17, the cardiologist reports that Ms. P’s atrial fibrillation is controlled. An ECG reveals mild left ventricular hypertrophy, an ejection fraction of 50% to 55%, no stenosis in the mitral or tricuspid valves, no valvular pulmonic stenosis, and moderate aortic sclerosis. Cardiac markers also are evaluated (creatinine phosphokinase: 105 U/L; creatinine kinase–MB fraction: 2.6 ng/mL; troponin: 0.01 ng/mL; pro-B-type natriuretic peptide: 2,073 pg/mL); and myocardial infarction is ruled out.

On Day 19, Ms. P’s diltiazem is consolidated to a controlled-delivery formulation, 180 mg/d, along with the addition of metoprolol, 12.5 mg twice daily. Ms. P is transferred back to the psychiatric unit.

OUTCOME Gradual improvement

On Days 20 to 23, Ms. P shows remarkable progress, and her mental status, cognition, and behavior slowly return to baseline. Haloperidol and valproic acid are tapered and discontinued. Ms. P is observed to be healthy and oriented to person, place, and time.

Continue to: On Day 25...

Pages

Recommended Reading

FDA issues warnings to companies selling illegal Alzheimer’s treatments
MDedge Psychiatry
Boosting Alzheimer’s trial participation via Medicare Advantage ‘memory fitness programs’
MDedge Psychiatry
Biogen, Eisai discontinue aducanumab Alzheimer’s trials
MDedge Psychiatry
New sleep apnea guidelines offer evidence-based recommendations
MDedge Psychiatry
Medical cannabis relieved pain, decreased opioid use in elderly
MDedge Psychiatry
AD biomarker not tied to increased interest in physician-assisted death
MDedge Psychiatry
Experts propose new definition and recommendations for Alzheimer’s-like disorder
MDedge Psychiatry
Lonely elderly patients suffer worse health outcomes
MDedge Psychiatry
Report on newly recognized cause of dementia should be read widely
MDedge Psychiatry
Coding variants in apolipoprotein B may be associated with early-onset Alzheimer’s disease
MDedge Psychiatry